All In Biotech

Drug Trial Radar · NCT00412061

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo

Last checked: Nov 19, 2026Latest source record: Nov 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 429 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

429

Actual

Start

Dec 2006

Primary completion

Apr 2010

Study completion Jun 2013

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 15, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.

Conditions

  • Carcinoid Tumor
  • Malignant Carcinoid Syndrome

Interventions

  • OctreotideDrug

    Octreotide 30 mg intramuscularly (i.m.) every 28 days.

  • PlaceboDrug

    A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.

  • EverolimusDrug

    A 10-mg oral daily dosing regimen (two 5-mg tablets) of everolimus.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) as Per Adjudicated Central Radiology ReviewTime frame: Time from randomisation to dates of disease progression, death from any cause or last tumor assessment, reported between day of first patient randomised, 10 January 2007, until cut-off date 02 April 2010

Locations

70 sites in 15 countries. Site status is shown where the registry gives one.

  • University of Arizona / Arizona Cancer Center Deptof Uof A/Arizona Cancer(2)

    Tucson, Arizona

  • Highlands Oncology Group The Center for Chest Care

    Fayetteville, Arkansas

  • Hematology Oncology Services of Arkansas

    Little Rock, Arkansas

  • Pacific Cancer Medical Center, Inc.

    Anaheim, California

  • Cedars Sinai Medical Center SC-2

    Los Angeles, California

  • University of California at Los Angeles UCLA New SC Address

    Los Angeles, California

  • University of Colorado Dept. of Univ. of Colorado

    Aurora, Colorado

  • Rocky Mountain Cancer Centers Dept of Rocky Mountain (2)

    Denver, Colorado

  • Eastern Connecticut Hematology & Oncology Associates Dept. of ECHO

    Norwich, Connecticut

  • Cancer Centers of Connecticut Southington Location

    Southington, Connecticut

  • Hematology Oncology PC Dept.of Hematology Oncology(2)

    Stamford, Connecticut

  • Ocala Oncology Center Dept. of Ocala Oncology Center

    Ocala, Florida

  • Cancer Care and Hematology Specialists of Chicagoland Niles

    Niles, Illinois

  • Indiana University Dept.of IndianaUniv.CancerCtr

    Indianapolis, Indiana

  • Central Indiana Cancer Centers CICC - South

    Indianapolis, Indiana

  • University of Iowa Medical Center Internal Medicine

    Iowa City, Iowa

  • University of Kansas Cancer Center Deptof Uof Kansas CancerCenter

    Kansas City, Kansas

  • Kansas City Cancer Center KCCC Business Office

    Overland Park, Kansas

  • Norton Cancer Institute Clinical Research Program

    Louisville, Kentucky

  • LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Deptof LSU Health Sciences (2)

    New Orleans, Louisiana

  • Mayo Clinic - Rochester Division of Hematology

    Rochester, Minnesota

  • Washington University School Of Medicine-Siteman Cancer Ctr Division of Oncology

    St Louis, Missouri

  • The Center for Cancer Care and Research

    St Louis, Missouri

  • Dartmouth Hitchcock Medical Center Medical Oncology

    Lebanon, New Hampshire

  • New York Oncology Hematology, P.C. Dept. of New York Oncology. PC

    Albany, New York

  • New York University Medical Center NYU Medical Center (2)

    New York, New York

  • Duke University Medical Center Dept. of Duke Cancer Center

    Durham, North Carolina

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Cancer Centers of the Carolinas CC of C -Eastside

    Greenville, South Carolina

  • Texas Oncology, P.A. Central Austin Cancer Center

    Austin, Texas

  • South Texas Institute of Cancer S. Tex Inst.- Corpus Christi

    Corpus Christi, Texas

  • Sammons Cancer Center - Texas Oncology Sammons Cancer Center (SC)

    Dallas, Texas

  • Texas Oncology, P.A. Forth Worth -- 12th Avenue

    Fort Worth, Texas

  • University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology

    Houston, Texas

  • Tyler Cancer Center

    Tyler, Texas

  • Virginia Oncology Associates VOA - Lake Wright

    Norfolk, Virginia

  • Northwest Cancer Specialists Compass Oncology -BKM

    Vancouver, Washington

  • University of Wisconsin / Paul P. Carbone Comp Cancer Center GI Oncology Research Center

    Madison, Wisconsin

  • Novartis Investigative Site

    Kogarah, New South Wales, Australia

  • Novartis Investigative Site

    Herston, Queensland, Australia

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.